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Network-based Drug Ranking and Repositioning
with respect to DrugBank Therapeutic
Categories
Matteo Re, and Giorgio Valentini
Abstract—Drug repositioning is a challenging computational problem involving the integration of heterogeneous sources of biomolecu-
lar data and the design of label ranking algorithms able to exploit the overall topology of the underlying pharmacological network. In this
context we propose a novel semi-supervised drug ranking problem: prioritizing drugs in integrated bio-chemical networks according to
specific DrugBank therapeutic categories. Algorithms for drug repositioning usually perform the inference step into an inhomogeneous
similarity space induced by the relationships existing between drugs and a second type of entity (e.g. disease, target, ligand set),
thus making unfeasible a drug ranking within a homogeneous pharmacological space. To deal with this problem, we designed a
general framework based on bipartite network projections by which homogeneous pharmacological networks can be constructed and
integrated from heterogeneous and complementary sources of chemical, biomolecular and clinical information. Moreover, we present
a novel algorithmic scheme based on kernelized score functions that adopts both local and global learning strategies to effectively rank
drugs in the integrated pharmacological space using different network combination methods. Detailed experiments with more than 80
DrugBank therapeutic categories involving about 1300 FDA approved drugs show the effectiveness of the proposed approach.
Index Terms—Drug ranking, drug repositioning, network integration, kernel functions, systems biology, graph nodes ranking
F
1 INTRODUCTION
D RUG repositioning, i.e. the prediction of novel ther-apeutic indications for existing drugs, has recently
raised the attention of the research community and of
the big pharma companies, since it allows substantial
savings in research and development spending with
respect to traditional drug development strategies [1].
Computational approaches for drug repositioning fo-
cused mainly on small-scale applications, such as the
analysis of specific classes of drugs or drugs for specific
diseases [2], [3], [4]. Large-scale applications, involving
a relatively large number of drugs and diseases, count
only a few examples [5], [6], [7], [8].
Different computational tasks related to the drug repo-
sitioning problem have been proposed, ranging from
clustering drugs either considering their pharmacophore
descriptors [2] or Connectivity Map-based networks [6],
to prediction of drug-target interactions [9], [10], or drug-
disease associations [11], [7] using supervised or semi-
supervised approaches. While the clustering approach
does not require “a priori” knowledge about drugs (but
should in principle require the application of methods
to assess the reliability of clustering results [12]), the
latter approach requires that at least a partial labeling
of the drugs is known in advance, and by exploiting the
available “a priori” knowledge, classical techniques to
evaluate supervised algorithms can be applied to assess
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the prediction performances [13]. For more details about
computational methods for drug repositioning based on
chemical similarity [2], molecular activity similarity [6],
[14], molecular docking [15], shared molecular patol-
ogy [16], and side effect similarities [17], we refer the
reader to the Dudley et al. comprehensive review [18].
In the context of semi-supervised learning of net-
work labeling, we propose a novel prediction task,
i.e. the large-scale ranking of drugs with respect to
DrugBank therapeutic categories (TCs) [19]. We chose
DrugBank categories since their associations to drugs
are manually curated using medical literature such as
PubMed, e-Therapeutics (http://www.e-therapeutics.ca)
and STAT!Ref (AHFS) (http://online.statref.com), and
because “at present, there is not a comprehensive and
systematic representation of known drugs indications
that would enable a fine-scale delineation of types of
drug-disease relationships” [18]. The ranking of drugs
for each DrugBank TC can allow the choice of top
ranked “false positive” drugs as natural candidates for
drug repositioning, while a pure classification approach
cannot provide such preferential candidates.
Several works showed that network integration plays
a central role in different molecular systems biology
problems [20], ranging from gene prioritization [21]
to gene function prediction [22] and drug reposition-
ing [23]. Unfortunately, in the context of drug reposi-
tioning, the inference step is usually performed into an
inhomogeneous similarity space induced by the relation-
ships existing between drugs and a second type of entity
(e.g. disease, target, ligand set), thus making unfeasible
a drug ranking within homogeneous pharmacological
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spaces. To deal with this problem, we propose a gen-
eral framework based on bipartite networks projections
for the construction of homogeneous pharmacological
spaces, by which, starting from heterogeneous networks
of data involving interactions between two different
sets of nodes (e.g. drug-protein targets, drug-pathways,
drug-side effects), we can obtain homogeneous drug-
drug networks that implicitly embed previous interac-
tions into homogeneous pharmacological spaces. The na-
ture of these network-structured projected spaces allows
the application of prediction algorithms to homogeneous
drug-drug networks that no longer represent a physical
reality, but informational constructs related to the phar-
macological similarity between drugs.
Most of the node label ranking algorithms proposed
for the analysis of biomolecular networks exploit local or
global learning strategies to properly rank nodes, accord-
ing to the biological property under investigation [24],
[25], [20]. In this work we propose a very fast semi-
supervised network method that combines both local
and global learning strategies to exploit both ”local”
similarities between drugs and ”global” similarities em-
bedded in the topology of the pharmacological network,
following an approach that we very recently successfully
applied to the gene function prediction problem [26] and
to discover genes related to diseases [27]. Indeed our
proposed Kernelized Score Functions can be considered a
generalization of both guilt-by-association methods [28],
and kernel based algorithms for semi-supervised net-
work analysis [29]. More precisely, we propose an al-
gorithmic scheme from which we can derive different
node/drug ranking algorithms by choosing or designing
a specific distance and/or a specific kernel well-suited
to capture the similarity between two nodes by possibly
exploiting the overall topology of the network.
We evaluated the proposed approach by integrat-
ing three pharmacological similarity spaces account-
ing, respectively, for chemical structure similarity, drug-
targets interaction similarity and drug-chemicals inter-
action similarity, in order to rank a curated set of U.S.
Food and Drug Administration (FDA) approved drugs
according to the DrugBank therapeutic categories.
A preliminary version of this paper has been presented
at the ISBRA conference [30]. This enhanced version
adds more details about the proposed methods, novel
experiments, including the comparison of different net-
work integration strategies, and an extended presenta-
tion and discussion of the results.
The paper is structured as follows: in Section 2 we
present  NetPro, Pharmacological Spaces Integration
based on Networks Projections, a method to construct
homogeneous pharmacological spaces from heteroge-
neous bipartite networks. Then we propose and discuss
different network combination methods to integrate pro-
jected networks obtained from heterogeneous sources of
“omic” data. In Section 3 we introduce the drug ranking
methods applied in this work, including our proposed
Score Functions based on Kernelized Random Walks. In the
successive section we provide a large set of experiments
involving 81 DrugBank TCs to show the effectiveness
of the proposed drug ranking and network construction
and integration methods. The conclusions summarize
the main results and developments of this work.
2  NetPro, PHARMACOLOGICAL SPACES IN-
TEGRATION BASED ON NETWORKS PROJEC-
TIONS
We propose  NetPro, Pharmacological Spaces Integra-
tion based on Networks Projections, a general approach
to construct and integrate different pharmacological sim-
ilarity spaces capturing different pharmacological char-
acteristics of drugs. In Section 2.1 we introduce the
bipartite network projection method to construct homo-
geneous spaces from inhomogeneous spaces represented
though bipartite networks, and in Section 2.2 we show
how to construct and integrate different pharmacological
spaces using different sources of chemical, biomolecular
and pharmacological data.
2.1 Bipartite networks projections
Many relationships naturally come in a bipartite setting.
In computational biology this kind of relationships can
be used, just to cite a few, for the investigation of
the interactions between proteins and genes or between
enzymes and metabolites using networks composed by
two types of nodes.
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Fig. 1. A toy bipartite network and its unipartite projec-
tions. (I) Original bipartite network. Top (>) nodes are
labeled by letters and bottom (?) nodes are labeled by
numbers. (II) Projection in the > domain. (III) Projection
in the ? domain.
Bipartite or two-mode networks (Fig. 1 I ) can be
naturally modeled as bipartite graphs. A bipartite graph
is a triplet B = (>;?; E) where > is the set of top nodes,
? is the set of bottom nodes, >\ ?= ; and E  > ?
is the set of edges. The difference with unipartite graphs
consists in the fact that the nodes lie in two disjoint
sets, and the edges are always between a node of one
set and a node of the other set. Bipartite networks can
be projected into one-mode networks (composed by a
single type of nodes). More precisely the >-projection of
B = (>;?; E) is the graph B> = (V >; E>) in which two
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nodes u; v 2 > are connected if they share at least one
neighbour x 2? in the original bipartite graph B. The
set of edges in the projected unipartite graph B> is thus:
E> = f(u; v);9x 2?: (u; x) 2 E ^ (v; x) 2 Eg (1)
The ?-projection B? is defined dually (Fig. 1). This
operation is commonly referred to as “binary mode
projection” and is suitable for the induction of a homoge-
neous similarity space between vertices v 2 > (or v 2?)
in the bipartite graph B (Fig. 1). In the following sections,
for the sake of simplicity, we name the projected graph
B> = (V >; E>) G = (V;E) and its adjacency matrix W .
The binary mode projection produces one-mode net-
works containing binary edges, but more complex pro-
jection schemes can generate real-valued edges accord-
ing to the edge weights in the bipartite two-mode
network, or to the number of shared neighbors, or to
the number of nodes which each shared neighbor is
connected to [31]. In our experiments we adopted the
binary projection technique, since the bipartite drug-
target data downloaded from the DrugBank database
are unweighted, and for homogeneity we applied a
binary projection also to the other considered data (see
Section 2.2 for more details). The bipartite network
projection scheme may induce different pharmacolog-
ical similarity spaces depending on the nature of the
bipartite network (e.g. drug-protein or drug-chemicals
interactions), and the projected networks correspond
to homogeneous pharmacological spaces representing
different notions of induced pharmacological similarity
between drugs.
2.2 Construction and integration of pharmacologi-
cal networks
Once projected onto one-mode networks G = (V;E), the
drug similarity spaces induced from the bipartite graphs
can be combined using appropriate network integration
methods and proper normalization techniques.
We adopted the normalized graph Laplacian L [32]
to make comparable the pharmacological networks G
represented through the corresponding symmetric ad-
jacency matrices W :
L =D 
1
2 (D  W )D  12 = I  D  12WD  12 (2)
where D is a diagonal matrix with elements dii =P
j wij , I is the identity matrix and wij are the elements
of the matrix W .
To combine the networks, we firstly adopted a pro-
gressive integration strategy, and secondly we exper-
imented with different network integration methods,
ranging form unweighted to weighted integration of the
pharmacological spaces.
In the rest of this section we first briefly introduce
the chemical and pharmacological data bases we used to
construct pharmacological spaces from different sources
of data (Section 2.2.1). Then we construct homoge-
neous pharmacological networks both directly consider-
ing the structural similarity between drug compounds
and by exploiting network projections from heteroge-
neous drug-target and drug-chemical spaces into ho-
mogeneous pharmacological networks (Section 2.2.2).
In Section 2.2.3 we present a progressive integration
strategy to efficiently exploit the different drug coverage
provided by each type of constructed pharmacological
network. Finally in Section 2.2.4 we describe different
network integration methods that we experimentally
compared in Section 4.5.
2.2.1 Chemical and pharmacological data bases.
We constructed three pharmacological similarity net-
works reflecting different notions of similarity between
drugs. The first (NstructSim), is based on edges encoding
the similarity of the chemical structures of the drugs.
This is the largest network considered in our experi-
ments and the only one that is not computed through
bipartite network projections. NstructSim is expected to
be the least informative pharmacological network, but
its usage is motivated by its full coverage of our ref-
erence set composed by 1253 drugs. The second one
(NdrugTarget) encodes a notion of drug similarity based
on common targets shared by different drugs. The last
network (NdrugChem) exploits information stored in the
STITCH database (in the form of precomputed scores)
in order to encode similarities between drugs based on
their shared interactions between the considered drugs
and other chemicals involved in their pharmacological
activity (this goes beyond the notion of similarity due to
shared protein-targets). Both NdrugTarget and NdrugChem
have been constructed from bipartite heterogeneous
networks projected into homogeneous pharmacological
spaces (that is networks having only drugs as their
nodes). All the aforementioned networks have been
constructed using data collected from the DrugBank [19]
and STITCH [33] public databases.
DrugBank is a unique bioinformatics and chemoinfor-
matics resource that combines detailed drug (i.e. chem-
ical) data with comprehensive drug target (i.e. protein)
information. In the current release DrugBank contains
detailed information about 6707 drug entries including
1436 FDA-approved small molecule drugs. In order to
construct a highly reliable drugs set we selected from
DrugBank the largest set of FDA approved drugs tar-
geting at least one FDA approved target. This led to the
definition of a collection composed by 1253 drugs.
STITCH integrates data distributed over many
databases. For instance, the chemical-chemical interac-
tion networks stored in STITCH includes information
about the impact of genetic variation on drug response
and from the Comparative Toxicogenomics Database
(which contains more than 8500 direct chemical-disease
relationships), thus ensuring the existence of drug-drug
relationships induced by common genetics and/or toxi-
cogenomics disease-association profiles [34], [35].
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Fig. 2. Progressive integration of network data.
2.2.2 Constructing pharmacological spaces from differ-
ent sources of data.
The construction of NstructSim is based on the direct
computation of the structural chemical similarities be-
tween each pair of drugs, while for the other pharmaco-
logical spaces we applied the projection techniques de-
scribed in Section 2.1. More precisely NstructSim has been
obtained by computing the Tanimoto similarity scores
between each pair of drugs in the reference set [36]. The
scores have been computed by comparing the molecu-
lar fingerprints of the simplified molecular input line
entry specification (SMILES) annotations contained in
DrugBank entries [37]. The chemical fingerprints have
been constructed using the get.fingerprint function of
the rcdk R package using, for the type parameter the
value extended because this type of fingerprint take rings
structures and atomic properties into account and is
thus expected to be more informative than the basic
fingerprint type computed by the get.fingerprint function.
The obtained adjacency matrix was then converted into
a binary matrix by thresholding the similarity scores.
Instead of tuning the threshold value we arbitrarily
adopted a threshold t = 0:5 because this is a commonly
adopted threshold as stated, among the others, in [9].
The second considered similarity space, NdrugTarget,
was obtained by creating a bipartite network between
the drugs and all the FDA approved targets, according to
the information stored in DrugBank. Once constructed,
this network has been projected onto a one mode net-
work and processed according to the procedures de-
scribed in Section 2.1.
The third pharmacological similarity space
(NdrugChem) has been constructed by processing the
chemical-chemical interactions stored in the STITCH 2.0
database [38]. A unique feature of STITCH is its ability
to establish relationships between chemicals based on
their shared relationships with other types of entities
such as phenotypic effects, interference with metabolic
pathways or co-occurrence in PUBMED abstracts.
These very different sources of information are used
to compute a chemical-chemical interaction score. The
amount of chemicals contained in the STITCH database
is larger than our reference set of 1253 drugs. We
constructed a bipartite network connecting the drugs
in our reference set with all the chemicals contained in
STITCH using the STITCH chemical-chemical similarity
scores. We then projected the resulting network onto
a homogeneous network composed only by the drugs
included in our reference set. In STITCH each predicted
drug-chemical interaction is stored along with a quality
score. The original bipartite graph encoding these
interactions has been sparsified by removing all the
interactions with score below 0:7. This threshold was
empirically selected by testing all the values ranging
from 0:5 to 0:9 at 0:1 steps, and searching for the larger
value able to cover, after the binary mode projection, at
least half of the drugs in our reference set (the vertices
of the NstructSim network). The thresholding led to a
final coverage of about 50% of the drugs in our reference
set.
2.2.3 Progressive integration of pharmacological net-
works.
The computed pharmacological networks have been
progressively integrated to enrich the encoded drug-
drug relationships with different and complementary
sources of information while preserving a high-coverage
of drugs for large scale drugs repositioning. To this end
we considered at first the NstructSim space alone (that
is the space with the highest drug coverage), then we
progressively integrated the other two pharmacological
spaces characterized by a lower coverage, that is respec-
tively NdrugTarget and NdrugChem. These progressively
enriched pharmacological networks have been repre-
sented through the corresponding adjacency matrices
W 1;W 2 and W 3, where the numeric index indicates
the number of different integrated pharmacological net-
works (Fig. 2). Despite the number of nodes/drugs in the
three networks is the same (1253), our “progressive inte-
gration” strategy yields to a significant increment in the
number of the edges, that grow from 13010, to 43827 and
96711 respectively inW 1;W 2 andW 3. This correspond
to a roughly 7:5 folds increment in the network density
(G) = 2mn(n 1) where m is the number of existing edges
and n is the number of nodes. The network densities of
the pharmacological spaces involved in our experiments
are 0:01658, 0:05587 and 0:12329 for W 1;W 2 and W 3
respectively. Fig. 5 (Supplemental Material) provides a
visual clue of the integrated W 3 network.
2.2.4 Network integration methods
To get more insights into the role of network integra-
tion methods in drug ranking, besides the progressive
integration described above, we considered also the
following methods:
 Unweighted Average (UA)
 Per-edge Unweighted Average (PUA)
 Max integration (MAX)
 Min integration (MIN)
 Weighted Average Per class (WAP)
 Weighted Average (WA)
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In the UA method the weight of each edge is com-
puted by simply averaging across the available n net-
works, and ”missing data”, i.e. pair of vertices vi, vj not
present in a given network result in a weight wij = 0:
wij =
1
n
nX
d=1
wdij (3)
The (Per-edge Unweighted Average - PUA) assures a
high coverage of the drugs included in the integrated
pharmacological network, without penalizing drugs for
which a specific source of data is unavailable. More
precisely, given a set of n pharmacological networks
Gd = (V d; Ed); 1  d  n, constructed through appro-
priate bipartite graph projections, the integrated phar-
macological network G = (V ; E), with V =
S
d V
d and
E  SdEd, can be derived by averaging the normalized
edge weights only when data for the corresponding pair
of drugs is actually available. In other words, if wdij
represents the weight of the edge (vi; vj) 2 Ed, the
weight wij of the edge (vi; vj) 2 E is computed as
follows:
wij =
1
jD(i; j)j
X
d2D(i;j)
wdij (4)
where D(i; j) = fdjvi 2 V d ^ vj 2 V dg.
The MAX integration selects the largest weight among
the available sources of data:
wij = max
d
wdij (5)
Analogously, theMIN integration selects the minimum
weight:
wij = min
d
wdij (6)
The above methods do not require to learn parameters
from the data, while the last two learn the ”weights” 
associated to each type of networks. The  parameter is
associated to the ”predictiveness strength” of each type
of network. For instance, it could be related to the Area
Under the Curve (AUC) or the precision at a given recall
obtained for a given therapeutic category (TC). More
precisely, having n networks and c TCs, we can compute
the weight d(k) for the dth network and for the kth TC
in the following way:
d(k) =
1Pn
j=1 F
j(k)
F d(k) (7)
where F d(k) represents the metric applied to measure
the accuracy of the prediction (e.g. the AUC or the
precision at a fixed recall) with respect to kth TC and
the dth network. The denominator in (7) simply assures
that
Pn
d=1 
d(k) = 1. The d(k) can be computed for
each TC k by estimating, e.g., the corresponding AUC
by leave-one-out on the training data.
Once obtained the d(k), the WAP method integrates
the networks in the following way:
wij(k) =
nX
d=1
d(k)wdij (8)
It is worth noting that in this way we construct a
different weighted integrated network for each TC.
We can also easily compute a ”regularized” weight
d, by averaging across classes. In this way we obtain a
unique weight d for each network:
d =
1
c
cX
k=1
d(k) (9)
The WA method, using the parameters (9) construct an
unique integrated network, independently of the TC
considered:
wij =
nX
d=1
wdij
cX
k=1
d(k)
c
=
nX
d=1
dwdij (10)
3 DRUG RANKING METHODS
Drug ranking can be formalized as a semi-supervised
node label ranking problem on a graph. Let G = (V;E)
be an undirected weighted graph, representing a phar-
macological network W , and let VC  V be a subset of
drugs belonging to a priori known therapeutic category
C. The drug ranking problem consists in finding a score
function S : V  ! R+, by which we can directly
rank vertices according to their likelihood to belong to
a specific therapeutic category C: the higher the score,
the higher the likelihood that a drug belongs to C. Drug
ranking can be seen as a “one-class” semi-supervised
learning problem on pharmacological networksW , since
we can exploit the labeling of the known positive vertices
v 2 VC belonging to the therapeutic category C, but also
the similarity relationships between labeled or unlabeled
vertices v 2 V .
In our experiments we compared results obtained with
random walks and random walk with restart with our
novel proposed method that can be interpreted as a
kernelized extension of the classical random walks. As a
baseline we applied a simple guilt-by-association-based
method.
3.1 Guilt by Association
Guilt by association (GBA) is a general biological prin-
ciple by which a biomolecular entity that interacts or
shares some features with another biomolecular entity
can also share some specific biological property. For
instance, if a gene A shares an expression patterns
or a genetic interaction with gene B and gene A is
annotated for a given Gene Ontology (GO) term, it
is likely that gene B can be annotated for the same
term [28]. In computational biology this basic biological
principle has been exploited to develop methods able to
assign a given biological or molecular property on the
basis of the labeling of neighborhoods in biomolecular
networks [24], [39]. In the context of pharmacological
networks (Section 2) we can assess the likelihood that
a given drug belongs to a given therapeutic category C
on the basis of the C-labeled drugs directly connected to
the drug under study.
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As a baseline, we implemented a simple version of
the GBA approach, by which a score for each node/drug
is computed by choosing the maximum of the weights
wij 2 W of the edges connecting the node vi with
positive labeled nodes vj 2 VC in the neighborhood N(i)
of vi:
S(vi; C) = maxj2N(i)wij (11)
where N(i) = fjjvj 2 VC ^ (vi; vj) 2 Eg.
3.2 Random Walks and Random Walks with Restart
Random walk (RW) algorithms [40] can capture not
only relationships coming from direct neighborhoods
between drugs, similarly to guilt by association methods,
but also relationships coming from shared and more in
general indirect neighbours between drugs. Indeed RW
ranks drugs by exploring and exploiting the topology of
the pharmacological network: random walks across the
network are performed starting from a subset VC  V of
drugs belonging to a specific therapeutic category C by
using a transition probability matrix Q =D 1W , where
W is the adjacency matrix, and D is a diagonal matrix
with diagonal elements dii =
P
j wij . The elements qij of
Q represent the probability of a random step from vi to
vj . The initial probability of belonging to the set of drugs
corresponding to a given TC can be set to po = 1=jVC j
for the drugs v 2 VC and to po = 0 for the drugs
v 2 V n VC : this represents the “a priori” knowledge
about the membership of the drugs to a specific TC,
and in principle these initial probabilities can be set to
different values for each drug (if we dispose of “a priori”
information detailed enough to justify this setting). Then
RW adopts an iterative strategy to update the probability
vector pt of finding a “random walker” at step t in the
nodes v 2 V :
pt+1 = Q
Tpt (12)
The update (12) is iterated until convergence or can be
stopped after a fixed number of steps if we would only
like to partially explore the topology of the network. We
could observe that the random walker could progres-
sively “forget” the a priori information available for the
therapeutic category C, by iteratively walking across the
overall network. To avoid this problem, we can stop the
RW algorithm after a few iterations, as outlined above,
or we can apply the random walk with restart (RWR)
method: at each step the random walker can move to one
of its neighbours or can restart from its initial condition
with probability :
pt+1 = (1  )QTpt + po (13)
It can be shown that the stationary distribution
of p in RWR is determined by the largest eigen-
value/eigenvector pair of the matrix Q0 = [I+(1 )Q]
obtained from (13), where I is the identity matrix, and
values of p at convergence determine the ranking of
the nodes [32]. With both RW and RWR methods at the
steady state we can rank the vector p to prioritize drugs
according to their likelihood to belong to the therapeutic
category under study.
3.3 Score Functions based on Kernelized Random
Walks
Random walks exploit the global topology of the net-
work (Section 3.2), while GBA methods introduce sim-
ple, but effective local learning strategies to rank nodes
according to the structure of their neighborhood. We
propose a novel method that on the one hand generalizes
the local learning strategy of GBA methods and on
the other hand adopts a global learning strategy by
embedding in a kernel function the random walking
across the network.
More precisely, we can define a distance measure
D(v; VC) between a drug v 2 V and the set of the
drugs x 2 VC in a reproducing kernel Hilbert space H,
according to a suitable mapping  : V ! H. For instance,
we can consider the minimum euclidean distance in the
Hilbert space H between a drug v 2 V and the set of
drugs VC belonging to a specific TC:
DNN (v; VC) = min
x2VC
n
(v)  (x)
n
2 (14)
By recalling that < (); () >= K(; ), where K :
V V ! R is a kernel function associated to the mapping
, we can choose in principle any valid kernel, but in this
context it is meaningful to use a random walk kernel [32]
constructed from the adjacency matrices W 1, W 2 and
W 3, since it provides a similarity measure that takes
into account direct and indirect relationships between
drugs in the pharmacological space. The Gram matrixK
associated to the one-step random walk kernel function
K(; ) is obtained from the adjacency matrix W of the
pharmacological network:
K = (a  1)I +D  12WD  12 (15)
where I is the identity matrix, D is the “degree” diag-
onal matrix with elements dii =
P
j wij and a is a value
larger than 2. The q-step random walk kernel is a slight
generalization of (15):
Kq = [(a  1)I +D  12WD  12 ]q (16)
where q  2 is an integer representing the number of
steps of the random walk across the graph and can be
easily computed by adopting a recursive strategy:
Kq =Kq 1K (17)
When q = 1 it is simply the one-step random walk kernel,
by which only the direct neighbours of each node are
visited. By setting q = 2, the random walks consider
also indirect neighbours, that is two nodes are similar if
either they are directly connected or they share common
nodes in their neighborhood. More in general, by setting
q > 2 two vertices are considered similar if they are
directly connected of if they are connected through a
path including from 1 to q   1 intermediate vertices. In
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principle also very long paths could be considered, but
this could introduce very remote similarities between
genes, leading to behaviours similar to that of diffusion
kernels [41]. The name of the kernel derives from the
fact that (16) is up to scaling terms equivalent to a q-
step random walk on the graph with random restarts,
a well-known algorithm used for scoring web pages in
the Google search engine [42].
By developing the square (14) we can derive the
following similarity measure:
SimNN (v; VC) =   min
x2VC
[K(v; v)  2K(v; x) +K(x; x)]
(18)
By assuming an equal auto-similarity K(x; x) for all
x 2 V , we can simplify (18), thus achieving the nearest
neighbours score SNN :
SNN (v; VC) =   min
x2VC
 2K(v; x) = 2 max
x2VC
K(v; x) (19)
It is easy to see that a different notion of distance based
on the first k nearest-neighbours leads to the definition
of the k-nearest neighbours score SkNN :
SkNN (v; VC) = 2
X
x2Ik(v)
K(v; x) (20)
with Ik(v) = fx 2 VC jx is ranked in the first k in VCg.
In a similar way we can also derive the average score
similarity measure SAV based on the average distance
DAV with respect to to the set of drugs VC belonging to
the C therapeutic category:
SAV (v; VC) =
2
jVC j
X
x2VC
K(v; x) (21)
The SAV score can be viewed as an extension of the
algorithm recently proposed in the context of gene func-
tion prediction from synthetic lethality networks [43].
Indeed by choosing different local learning strategies
and/or specific kernels well-suited to capture the global
topology of the network, we can derive different ranking
algorithms, including those proposed in [43]. By using
the proposed kernelized score functions we can rank
drugs with respect to their likelihood to belong to a given
therapeutic category C simply by evaluating the selected
kernel function. If the kernel matrix is computed in
advance, the time complexity of the proposed algorithm
is O(jVC jjV j), that is approximately linear with respect
to the number of drugs when jVC j << jV j.
4 RESULTS AND DISCUSSION
We propose a novel learning problem in the context of
drug ranking and repositioning: the prediction of the
therapeutic category of drugs according to the annota-
tions provided by DrugBank 3.0. The ranking algorithms
described in Section 3 and the  NetPro construction and
integration of the pharmacological networks W 1;W 2
and W 3 (Section 2) have been applied to predict the
DrugBank TCs of drugs.
Binary network matrices of the constructed
pharmacological spaces and DrugBank labels
used in the experiments are available from:
http://homes.di.unimi.it/re/DATA/ISBRA-
DrugData.
4.1 Experimental Setup
In order to obtain the TC labels, we parsed the DrugBank
entries belonging to our reference set (1253 FDA ap-
proved drugs, see Section 2.2.1) by extracting all the drug
category annotations excluding the chemical categories
(categories reflecting the chemical nature of the consid-
ered compounds). We firstly analyzed TCs associated to
more than 15 drugs obtaining 51 therapeutic classes, in
order to exclude classes with too few positive examples
to assure reliable predictions. The classes represented in
this set are very broad in nature ranging, only to cite
a few, from “Diuretics” to “Anti Bacterial Agents” and
to “Antiparkinson Agents”, and are characterized by a
relatively high unbalance between labeled and unlabeled
nodes (Table 1 of Supplemental Material). Then, to test
the effectiveness of our methods with TCs characterized
by a small number of known associated drugs, we
analyzed a set of randomly selected TCs with less than
15 annotated drugs.
While GBA and RW iterated till to convergence have
no parameters, for RWR we run the algorithm with
 2 f0:1; 0:3; 0:6; 0:9g, and we run also the version of
the RW algorithm with a limited number of iterations,
by varying the number of steps q 2 f1; 2; 3; 5; 10g. Also
for the proposed score functions with random walk
kernel we varied the number of steps in the same range
(q 2 f1; 2; 3; 5; 10g).
We also evaluated the impact of different network in-
tegration strategies on the overall ranking performances.
More precisely we compared the results obtained with
the network integration methods described in Sect. 2.2.4.
The  parameters (weights associated to each pharma-
cological network) have been computed using the AUC
metric (see (7) in Sect. 2.2.4) estimated through leave-
one-out techniques on the training data.
In our experiments we did not perform a fine tuning of
the method’s parameters for each class; we simply fixed
the same parameters for all classes and chose the ones
leading to the best results. It is worth noting that a fine
tuning of the parameters for each class (e.g. by internal
cross-validation) may lead to better overall results.
We evaluated the proposed ranking method by using
a 5-folds cross validation scheme repeated 10 times. As
we are interested in evaluating the ranking of the drugs
with respect to the TCs, we computed the Area Under
the ROC curve (AUC), and the precision at fixed recall
levels by varying recall between 0:1 and 1 at 0:1 steps.
In Section 4.2 we present the compared AUC and
precision at a given recall averaged across the therapeu-
tic classes, while results obtained with DrugBank TCs
characterized by a very low cardinality are available in
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TABLE 1
Average AUC and precision at 40% recall across the DrugBank categories with more than 15 drugs.
Methods AUC P40R
W1 W2 W3 W1 W2 W3
SAV 3 steps 0.8332 0.9233 0.9372 0.5330 0.6497 0.6931
SkNN 2 steps k=31 0.8373 0.9261 0.9361 0.5334 0.6480 0.7012
SNN 3 steps 0.8271 0.9067 0.9224 0.3803 0.4300 0.4653
RWR  = 0:6 0.8078 0.9203 0.9299 0.5238 0.6278 0.6839
RW 1 step 0.8175 0.9201 0.9272 0.4910 0.6240 0.6799
GBA 0.8027 0.9028 0.9095 0.3273 0.4127 0.4634
RW 0.6846 0.5780 0.5334 0.2224 0.0608 0.0366
the Supplemental Material. In Section 4.3 we discuss
the influence of the choice of the number of steps in
random walk kernel score functions, and in Section 4.4
we report the AUC and precision at a fixed recall results
for each TC. In Section 4.5 we compare different network
integration methods to evaluate their impact on on the
DrugBank ranking task, and in Section 4.6 we report a
preliminary analysis of the top ranked false positives as
possible candidates for drug repositioning.
4.2 Average AUC and Precision at a Fixed Recall
Results
Tab. 1 shows the AUC and precision at 40% recall
(P40R) averaged across the 51 DrugBank therapeutic
classes with more than 15 drugs, using the progressive
integration of pharmacological networks (Sect. 2.2.3). For
kernelized score functions, RWR and RW at fixed steps
the parameters giving the best results are highlighted in
bold.
Independently of the considered methods, the average
AUC and P40R increases as new pharmacological spaces
are added: most of the AUC increment is achieved
when we integrate 2 pharmacological spaces (W 2), but
note that the relatively small increment obtained, e.g.
by SkNN , when we pass from 2 to 3 integrated phar-
macological spaces is actually statistically significant
according to the Wilcoxon paired signed rank test (p-
value< 0:005). With P40R results the increment is large
also when we pass from W 2 to W 3. These results are
enforced by the precision at fixed recall levels curves
(Fig. 3): independently of the recall level and the consid-
ered ranking methods, precision withW 3 is larger than
precision with W 2 and W 1 pharmacological networks.
An exception is represented by the classical RW iter-
ated till to convergence: it deteriorates its performances
when new sources of data are added (Tab. 1). Note
that RW substantially fails in these ranking tasks, since
just with W 1 (i.e. considering only the raw chemical
similarities between drugs) this method is significantly
worse than all the other ones. This is likely due to the fact
that the random walk is performed until the convergence
condition is reached, thus resulting in an exploration
of too remote and not significant relationships between
drugs. Indeed both RW 1 step and RWR achieve signifi-
cantly better results, since they do not “forget” the initial
conditions, by exploring only the direct neighborhood
of each drug (RW 1 step) or by restarting with a certain
probability  from the initial conditions (RWR).
The average AUC and P40R are always higher in SAV
and SkNN with respect to the other compared methods
(Tab. 1), and the differences across the TCs are always
statistically significant (p-value< 0:005, Wilcoxon paired
signed rank test) except for the AUC with W 1 with
respect to SNN , and between SAV and RWR and RW
1 step with W 2. Quite surprisingly, the simple GBA
method achieves very good average results in terms of
AUC, while with P40R (Tab. 1) and more in general
with precision at fixed recall levels we observe a larger
decay with respect to the other considered methods
(Fig. 3). Note that a similar behaviour can be observed
also in SNN , even if SNN often obtains significantly
better results than GBA both in terms of AUC and
P40R: both methods adopt a ”nearest-neighbour” local
learning strategy to compute the score associated to each
drug (see (11) and (19)), but SNN embeds a random
walk kernel that can exploit the overall topology of the
network.
Summarizing, the integration of multiple sources of
information into projected homogeneous pharmacolog-
ical spaces plays a central role to significantly improve
the ranking results. Moreover random walk kernel score
functions and in particular SAV and SkNN achieve signif-
icantly better results than the other compared methods.
According to these results, as a “rule of thumb” we
suggest to apply SAV and SkNN score functions with
2 or 3 steps random walk kernels to rank drugs in
the constructed pharmacological space. This recommen-
dation comes from the analysis of the experimental
results, and can be explained by the fact that usually
”relatively close” neighbours are highly informative: by
exploring long paths across the pharmacological space
(i.e. by allowing a too large number of steps) we con-
sider similarities mediated through multiple drugs in
the network, thus introducing in several cases noise
into the prediction score. Of course this depends also
on the nature of the data and on the characteristics of
the considered TC: for instance if we consider networks
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Fig. 3. Precision at fixed recall levels, averaged across the 51 therapeutic DrugBank classes with more than 15
annotated drugs, withW 1,W 2 andW 3 pharmacological networks. (a) SkNN ; (b) SAV ; (c) SNN ; (d) RWR; (e) RW 1
step; (f) GBA.
TABLE 2
Compared AUC and precision at 40% recall for SAV with 1, 2, 3, 5 and 10 steps random walk kernels. Results are
averaged across the DrugBank categories with more than 15 drugs.
N. of steps AUC P40R
W1 W2 W3 W1 W2 W3
1 step 0.8274 0.9252 0.9303 0.5206 0.6355 0.6996
2 steps 0.8373 0.9261 0.9360 0.5336 0.6482 0.7005
3 steps 0.8332 0.9233 0.9372 0.5330 0.6497 0.6931
5 steps 0.8226 0.9235 0.9365 0.5312 0.6452 0.7005
10 steps 0.8129 0.9239 0.9370 0.5319 0.6483 0.6955
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Fig. 4. Counts of the ”wins” across the therapeutic classes for the SAV score with 1, 2, 3, 5 and 10 steps random walk
kernels, withW 1,W 2 andW 3 pharmacological networks: (a) Wins with respect to AUC; (b) Wins with respect to the
precision at 40% recall. Note that the sum of wins for each network is larger than the number of TCs: this is due to the
“ties” of winning methods.
constructed using the chemical similarity between drugs
and a TC well characterized from a chemical standpoint
(e.g. Cephalosporins) 1-step RW kernels work nicely, but
using networks obtained from drug-chemical interac-
tions, if the drugs are involved in the same pathway rel-
evant for a specific TC, it is possible that by introducing
more than 2-3 steps we can also achieve better results.
To better understand this topic, in the next section, we
performed some experiments to analyze the influence of
the choice of the number of steps in kernelized score
functions for specific TCs.
We performed experiments also with “small” Drug-
Bank TCs, including less than 15 drugs (Table 4 in
Supplemental Material). Average AUc and P40R across
classes, as expected, register a certain decrement with
respect to ”large” TCs with more than 15 drugs. Very
interestingly, the network integration introduces a more
consistent increment in both AUC and P40R: all the
methods approximately double the precision passing
fromW 1 toW 3, and SAV and SkNN with random walk
kernels achieve the best results. A full description and
discussion of the experimental results with ”small” TCs
is available in the Supplemental Material.
4.3 Influence of the Number of Steps in Random
Walk Kernel Score Functions
To get more insights into the significance of the number
of steps needed to effectively rank drugs in pharmaco-
logical networks, we compared the average AUC and
P40R results of SAV with 1, 2, 3, 5 and 10 steps random
walk kernels. Values in boldface highlight the best aver-
age results in terms of AUC and P40R achieved withW 1,
W 2 and W 3 (Tab. 2). Interestingly enough, with most
pharmacological networks, there is no a statistically sig-
nificant difference between 2, 3, 5 and 10 steps random
walk kernels according to the Wilcoxon paired signed
rank test, at 0:005 significance level (for instance, in terms
of AUC withW 2 andW 3 and in terms of P40R with all
the three pharmacological spaces). Recalling that 3 steps
SAV has been chosen as the best SAV in terms of AUC
(see Tab. 1), we can conclude that also increasing the
number of steps, on the average, there is no performance
decay in terms of average AUC and P40R.
To gain more insights into the reasons underlying
this learning behavior, we counted how many times
each k-steps random walk kernel achieved the maximal
AUC or P40R (Fig. 4) across TCs. For a specific TC,
we say that a method “wins” if its AUC or P40R is
the largest among all the considered methods. More
precisely, we analyzed the number of “wins” in terms
of AUC and P40R among SAV with 1, 2, 3, 5 and 10
steps random walk kernels. We can observe that the
“wins” are quite distributed across the random walk
kernels with a different number of steps, especially if
we consider the P40R (Fig. 4 (b)), while for the AUC
(Fig. 4 (a)) we can observe a quite interesting “peak of
wins” for the 10 steps random walk kernel with the
full integrated W 3 pharmacological space. A possible
explanation of these results could consists in the fact that
STITCH data involve also drug-chemical interactions: if
different chemicals are part of a pathway relevant for
the TC under study, and if they are targets of different
drugs, it is possible that in the projected pharmacological
space also drugs “relatively far” from each other (in
terms of the weighted path interconnecting them), could
be ”pharmacologically connected”, since they act on the
same pathway relevant for the TC under study.
These results show that, according to the specific
characteristics of each therapeutic class, different number
of steps should be considered, in order to take into
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account, at least for some classes, also “indirect” sim-
ilarities mediated through relatively long paths across
the pharmacological space.
4.4 Per Class AUC and Precision at a Fixed Recall
Results
Fig. 1 in the Supplemental material provides a global
view of the AUC results achieved by each drug ranking
method for each DrugBank TC. The TCs are sorted
according to the AUC values obtained by SAV with the
W 3 pharmacological network. For RW we mean 1-step
Random Walk (recall that by running classical RW till
to convergence we obtain poor results). In Fig. 1 and 2
in the Supplemental material, for each method we used
the parameters listed in Tab. 1. For the correspondences
between the TC name abbreviations used in Fig. 1 and
2 and the full DrugBank names, please see Tab. 1 in
Supplemental Material.
By moving fromW 1 (Fig. 1 (a)) toW 2 (Fig. 1 (b)) and
W 3 (Fig. 1 (c), Suppl. material), the heatmap “tones”
from yellow to dark red, showing the effectiveness of the
 NetPro approach, independently of the considered drug
ranking method. The “color key” at the top left of each
figure shows also an histogram of the distribution of
AUC values across classes and across methods, showing
a clear skewness towards high AUC values when we
move from W 1 to W 3. The same general trend can be
also observed with the precision at 40% recall (Fig. 2,
Supplemental material), even if in this case the results
are distributed across a wider range of values. Note that
the AUC values across classes are highly correlated be-
tween methods: this is more apparent with AUC, while
in terms of P40R a very high correlation is maintained
only between SkNN and SAV (the methods achieving the
best results on the average) and partially between RW
and RWR. GBA and SNN show a high correlation both
in terms of AUC and P40R: this fact confirm the consid-
erations introduced in Section 4.2 about the similarity
of the score functions characterizing these methods. The
correlation between methods tend to increase when we
use the integrated W 3 pharmacological network, show-
ing another time the key role of the projections and the
integration to improve the overall ranking performances.
While for some TCs such as “Penicillins” or
“Cephalosporins” we can obtain high AUC values just
withW 1 (see the first two rows of the heatmap in Fig. 1
(a), Supplemental material), for other categories the in-
tegration of drug-target and drug-chemicals interaction
information is of paramount importance to improve
performances: consider, for instance, “Anticonvulsants”
or “Anti-HIV Agents”. This is not surprising since both
Penicillins and Cephalosporins are highly characterized
from a chemical standpoint (the average Tanimoto struc-
tural similarities in these classes are 0:6743 and 0:6112
respectively versus an average Tanimoto similarity of
0:1748 in the whole drugs reference set) and hence can
be effectively predicted by using the similarities between
their chemical structures, while for other chemically
more heterogeneous TCs, such as “Anti-HIV Agents”,
drug-target or drug-chemicals relationships play a cen-
tral role for their characterization.
This is also more evident when we consider the pre-
cision (Fig. 2, Supplemental material). Several TCs need
the  NetPro projection and integration to achieve an ac-
ceptable precision: for instance “Antiparkinson Agents”
and “Antidyskinetics” substantially increment their
P40R values while moving from W 1 to the fully in-
tegrated W 3 pharmacological network, by exploiting
drug-drug relationships induced by common genetics
and/or toxicogenomics disease-association profiles. An-
other case is represented by “Anti.Ulcer Agents”, for
which Tanimoto coefficients are ineffective (Fig. 2 (a),
third row of the heatmap in the Supplemental material),
while withW 2 andW 3 we can obtain a very significant
P40R increment.
For most classes SkNN and SAV achieve the best
results, and also with respect to the worst ranked TCs we
can obtain reasonable results (see Tab. 2 in Supplemental
Material). These results show that for several classes
we could obtain better results by integrating further
informative sources of data projected into homogeneous
pharmacological spaces through  NetPro.
4.5 Comparison of Network Integration Methods
In this section we compare the results obtained using the
networks integration methods presented in Section 2.2.4.
We considered the ranking tasks involving the 51 Drug-
Bank TCs with more than 15 drugs (Table 1 of Sup-
plemental Material). The performance values have been
estimated in terms of AUC averaged across all the TCs
(Table 3) and in terms of precision at 40% recall (Table 4),
using a stratified 5 folds cross validation repeated 10
times. In the left part of Table 3 and 4, are reported
the results obtained with a single network: structSim
is the network representing the direct chemical similar-
ities between drugs; drugTarget is the pharmacological
network obtained by network projections from Drug-
Bank bipartite drug-target networks, and drugChem the
network obtained from the bipartite chemical-chemical
networks from the STITCH data base (see Section 2.2.2).
The average results across TCs show that the most
informative network is drugTarget, both in terms of
AUC and P40R, while the worst results are obtained with
drugChem, at least in terms of average P40R. However
we warn the reader that this comparison should be
considered with caution, since the three networks are
composed by different sets of drugs: indeed structSim
is the largest one, while drugTarget includes most but
not all the nodes/drugs of structSim, and drugChem
approximately half of the nodes of structSim (see Sec-
tion 2.2 for more details).
In the right side of Table 3 and 4 are summarized
the results obtained with different network integration
methods. Independently of the ranking method used
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TABLE 3
Comparison of network integration strategies: average AUC across the DrugBank categories.
Ranking methods Single networks Network integration methods
structSim drugTarget drugChem WA WAP UA PUA MAX MIN
SAV 1 step 0.6455 0.7934 0.7657 0.9307 0.9291 0.9300 0.9301 0.9286 0.0772
SkNN 2 steps k=31 0.8215 0.8853 0.7862 0.9365 0.9367 0.9351 0.9361 0.9346 0.2193
SNN 3 steps 0.8271 0.8847 0.7849 0.9224 0.9227 0.9216 0.9219 0.9176 0.2338
RWR  = 0:6 0.7850 0.8930 0.7733 0.9253 0.9251 0.9227 0.9241 0.9206 0.3095
RW 1 step 0.6417 0.7682 0.7428 0.9219 0.9201 0.9212 0.9209 0.9187 0.0752
GBA 0.5911 0.7547 0.7572 0.9081 0.9048 0.9083 0.9074 0.9046 0.0662
RW 0.6567 0.5468 0.5294 0.5654 0.5833 0.5633 0.5633 0.5603 0.1378
TABLE 4
Comparison of network integration strategies: average precision at 40% recall across the DrugBank categories.
Ranking methods Single networks Network integration methods
structSim drugTarget drugChem WA WAP UA PUA MAX MIN
SAV 1 step 0.5205 0.5289 0.4531 0.7031 0.6876 0.6791 0.6801 0.6546 0.2633
SkNN 2 steps k=31 0.5333 0.5426 0.4668 0.6949 0.7008 0.6818 0.6808 0.6675 0.2673
SNN 3 steps 0.3800 0.3727 0.3639 0.4618 0.4678 0.4586 0.4589 0.4236 0.2410
RWR  = 0:6 0.5200 0.5467 0.4340 0.6855 0.6875 0.6809 0.6727 0.6481 0.2515
RW 1 step 0.5024 0.5142 0.4165 0.6721 0.64361 0.6620 0.6753 0.6216 0.2613
GBA 0.3099 0.3433 0.2812 0.3964 0.3764 0.3886 0.3869 0.3492 0.2174
RW 0.1882 0.1063 0.0418 0.0429 0.0474 0.0373 0.0372 0.0370 0.1975
(except for RW), network integration assures a sub-
stantial increment of both AUC and P40R. Interestingly
enough, this increment is common to all the considered
network integration methods (except for MIN), and the
best results are comparable with those obtained with
the progressive integration method (Table 1). The best
performing network integration strategy for each rank-
ing method is highlighted in bold. Table 3 and 4 show
that the best results are achieved with the weighted
integration methods WA and WAP, even if the difference
with respect to the other non-weighted methods is not
always statistically significant according to the Wilcoxon
rank sum test (at 0:005 significance level). Among the
considered network ranking methods, kernelized score
function SAV and SkNN achieve the best results, espe-
cially with the P40R metric (the difference is statistically
significant at 0:005 significance level according to the
Wilcoxon rank sum test).
These results show that even if the best results are
obtained with the weighted average techniques (WA
and WAP), that take into account the accuracy of the
ranking methods on each different network, also the
non-weighted integration methods (UA, PUA, MAX)
may achieve competitive results, without the overload
of computing the weights for each separated network.
4.6 Preliminary Analysis of Top Ranked False Posi-
tives
A thorough analysis of the results relative to each TC
is out of the scope of this investigation, but to show
the potential of the proposed method, we report the
analysis of the top ranked false positives predicted
in three drug categories. All the ranking results show
an AUC increment due to the integration of different
pharmacological networks, and we chose among them
three of the classes with the largest AUC improvement.
“Antidyskinetics” drugs are used in the treatment of
motor disorders. In this ranking task we obtained 0:730,
0:887 and 0:923 average AUC using the W1, W2 and
W3 networks respectively. The first top ranked negative
(L-Tryptophan, DrugBank id: DB00150) was reported
to be effective in preventing levodopa-induced motor
complications in the treatment of patients affected by
Parkinson disease [44], and hence could be associated
to the “Antidyskinetics” category. In the ranking task
associated with the “Anti HIV Agents” category we
achieved respectively 0:753, 0:900 and 0:943 AUC results
using our progressively integrated networks. The first
top ranked negative was Darunavir (DB01264) and, ac-
cording to the associated DrugBank entry, it is indicated
in the treatment of HIV, but not annotated as “Anti HIV
Agents”, probably since it was just annotated as “HIV
Protease Inhibitors”. The top ranked false positive in
the task associated with the “GABA Modulators” (AUC
0:941, 0:972 and 0:995) is Adinazolam (DB00546). This
drug, and the four top ranked false positives in this
task are benzodiazepines, a class of substances known
to modulate the effect of GABA [45].
5 CONCLUSIONS AND DEVELOPMENTS
The combination of bipartite network projections,
weighted integration of different pharmacological spaces
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and kernelized score functions with random walk ker-
nels plays a key role to significantly improve the drug
ranking results with respect to DrugBank TCs.
Our proposed kernelized scores SAV and SkNN , by
introducing both local and global learning strategies for
the semi-supervised ranking of drugs, achieve signifi-
cantly better results than the other compared methods.
We outline that we proposed a general algorithmic
scheme for drug ranking from which different algo-
rithms can be derived by choosing appropriate distance
measures and by designing kernels well-suited to cap-
ture the structural and functional similarities between
drugs in the underlying pharmacological space. From
this standpoint we think that novel research could build
on our results to design novel algorithms for drug
ranking and repositioning and to construct novel drug
networks embedding more information derived from
properly chosen heterogeneous bipartite networks.
Indeed in our experiments we integrated three dif-
ferent pharmacological spaces, but the same network
projection and integration approach can be applied to
enrich the pharmacological space with new information
coming, e.g., from annotated side-effects (as the one
stored in public databases such as SIDER [47]), or from
manually curated pathways databases such as Reac-
tome [48], or from large collections of gene expression
signatures as the ones included in the Connectivity
Map public repository [5], or also from data obtained
through Next Generation Sequencing techniques, one of
the most promising biotechnologies for drug discovery
and development [49].
According to our experimental results and consider-
ations about the characteristics of the pharmacological
spaces, we recommend firstly to apply SAV or SkNN
score functions with 2-3 steps random walk kernels,
since these method and parameter settings achieve, on
the average, the best results. Nevertheless, the analysis
of the performances of the score functions embedding
random walk kernels with different numbers of steps
(Section 4.3), shows that also indirect similarities medi-
ated through relatively long paths across the pharmaco-
logical space can be relevant to correctly rank drugs with
respect to DrugBank TCs. These results suggest that by
tuning the number of steps for each TC or by adopting
ensemble learning strategies [46] to include and combine
random walk kernels with different number of steps may
significantly improve the performances of the kernelized
score functions.
It is worth noting that even if our proposed methods
provide basically a ranking of the drugs with respect to a
TC without an explanation of the reasons why an associ-
ation drug-TC is made, we can derive an interpretation
of the results, at least if we apply a relatively simple
algorithm from our algorithmic scheme. For instance, if
we apply a SNN score with a 1-step RW kernel to a phar-
macological network obtained from a bipartite drug-
target network, an association of a drug d and a TC T
can be explained by the fact that another drug d0, known
to be associated to T , has a common target with d, and
this target is relevant for the therapeutic category under
study. Of course the interpretation of an association
become difficult if we use more complex score functions,
such as a 5-steps RW kernel or a diffusion kernel. In these
more general cases, our algorithms explore large parts of
the network, thus implicitly considering a multiplicity of
functional similarities embedded in the pharmacological
network, as well as subtle and ”remote” relationships
between drugs. In these conditions a clear explanation of
the reasons why an association is made is very difficult
or not feasible at all.
We would like also to outline that kernelized score
ranking methods could be applied to larger drug net-
works, due to their low computational complexity and
scalability. Indeed the full ranking of drugs with 5 fold
CV repeated 10 times with respect to the 81 considered
TCs requires no more than 10 seconds on an Intel i7-
860 2.80 GHz processor with 4 Gbytes of RAM. Hence,
considering that in our experiments we analyzed about
a thousand of FDA-approved drugs, we hypothesize
that the same approach could be applied to thousands
of investigational compounds, thus potentially finding
initial therapeutic indications for unknown drugs.
We experimented with relatively simple binary net-
work projections, but other approaches based on sim-
ple thresholding on the number of bipartite edges, or
weighted bipartite projections could improve the ro-
bustness of the resulting homogeneous networks in the
pharmacological space. We think that the analysis and
development of novel network projection algorithms,
well-suited to the characteristics of drug ranking and
drug repositioning problems, is a promising research line
that could be explored in future research work.
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